News
The Semaglutide peptide has emerged as a compelling subject in biochemical and physiological research due to its potential ...
A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...
Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide — are now available in the Indian market. Here’s how they work, how ...
GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...
According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...
Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating ...
A clinical trial led by an Indiana University School of Medicine researcher found that weekly doses of semaglutide - a ...
GLP-1 therapies primarily use single-use injectable pens, contributing to medical waste challenges. The pharmaceutical ...
GLP-1 receptor agonists may increase the risk of several autoimmune diseases in adults with type 2 diabetes, according to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results